Lucence offers expanded cfRNA version LiquidHallmark

By LabPulse.com staff writers

January 10, 2022 -- Oncology company Lucence has released an expanded version of its LiquidHallmark biopsy assay that now includes cell-free RNA (cfRNA) profiling in addition to cfDNA.

Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."

Lucence's LiquidHallmark cfDNA and cfRNA panel combines cfRNA profiling of 27 actionable fusions with cfDNA profiling of mutations in 80 genes, it said.

Lucence, Yemaachi team up on liquid biopsy study in Africa
Oncology company Lucence and Ghana-based cancer research firm Yemaachi Biotech are collaborating on a study aimed at characterizing the genomics of breast...
Lucence, Waseda University partner on liquid biopsy test
Lucence and Waseda University in Japan will develop a liquid biopsy laser-based imaging platform for early cancer detection. The technology captures thousands...

Copyright © 2022 LabPulse.com

Last Updated ls 1/10/2022 4:44:06 PM